Annual CFO
-$9.56 M
+$871.10 K+8.35%
December 1, 2023
Summary
- As of February 8, 2025, KPRX annual cash flow from operations is -$9.56 million, with the most recent change of +$871.10 thousand (+8.35%) on December 1, 2023.
- During the last 3 years, KPRX annual CFO has fallen by -$2.24 million (-30.61%).
- KPRX annual CFO is now -905.37% below its all-time high of -$950.60 thousand, reached on December 31, 2014.
Performance
KPRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
$920.10 K
+$4.65 M+124.65%
September 1, 2024
Summary
- As of February 8, 2025, KPRX quarterly cash flow from operations is $920.10 thousand, with the most recent change of +$4.65 million (+124.65%) on September 1, 2024.
- Over the past year, KPRX quarterly CFO has increased by +$3.44 million (+136.50%).
- KPRX quarterly CFO is now -93.25% below its all-time high of $13.62 million, reached on March 1, 2024.
Performance
KPRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
$8.23 M
+$3.44 M+71.85%
September 1, 2024
Summary
- As of February 8, 2025, KPRX TTM cash flow from operations is $8.23 million, with the most recent change of +$3.44 million (+71.85%) on September 1, 2024.
- Over the past year, KPRX TTM CFO has increased by +$17.33 million (+190.40%).
- KPRX TTM CFO is now at all-time high.
Performance
KPRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
KPRX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +8.3% | +136.5% | +190.4% |
| 3 y3 years | -30.6% | +166.4% | +186.2% |
| 5 y5 years | +11.9% | +166.4% | +186.2% |
KPRX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +10.5% | -93.3% | +124.7% | at high | +173.4% |
| 5 y | 5-year | -30.6% | +10.5% | -93.3% | +124.7% | at high | +173.4% |
| alltime | all time | -905.4% | +11.9% | -93.3% | +122.4% | at high | +173.4% |
Kiora Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $920.10 K(-124.6%) | $8.23 M(+71.9%) |
| Jun 2024 | - | -$3.73 M(-127.4%) | $4.79 M(-32.9%) |
| Mar 2024 | - | $13.62 M(-627.8%) | $7.14 M(-174.7%) |
| Dec 2023 | -$9.56 M(-8.4%) | -$2.58 M(+2.4%) | -$9.56 M(+5.0%) |
| Sep 2023 | - | -$2.52 M(+82.0%) | -$9.10 M(-4.7%) |
| Jun 2023 | - | -$1.38 M(-54.9%) | -$9.55 M(-10.4%) |
| Mar 2023 | - | -$3.07 M(+44.2%) | -$10.67 M(+2.3%) |
| Dec 2022 | -$10.43 M(-2.3%) | -$2.13 M(-28.3%) | -$10.43 M(-7.0%) |
| Sep 2022 | - | -$2.97 M(+18.8%) | -$11.22 M(+6.6%) |
| Jun 2022 | - | -$2.50 M(-11.8%) | -$10.52 M(-3.8%) |
| Mar 2022 | - | -$2.83 M(-3.0%) | -$10.94 M(+2.5%) |
| Dec 2021 | -$10.68 M(+45.9%) | -$2.92 M(+28.6%) | -$10.68 M(+12.8%) |
| Sep 2021 | - | -$2.27 M(-22.1%) | -$9.47 M(+5.9%) |
| Jun 2021 | - | -$2.92 M(+13.4%) | -$8.94 M(+19.3%) |
| Mar 2021 | - | -$2.57 M(+50.3%) | -$7.49 M(+2.3%) |
| Dec 2020 | -$7.32 M(-10.3%) | -$1.71 M(-1.8%) | -$7.32 M(-10.7%) |
| Sep 2020 | - | -$1.74 M(+18.6%) | -$8.19 M(-3.1%) |
| Jun 2020 | - | -$1.47 M(-38.9%) | -$8.45 M(+0.5%) |
| Mar 2020 | - | -$2.40 M(-7.2%) | -$8.41 M(+3.1%) |
| Dec 2019 | -$8.15 M(-24.8%) | -$2.59 M(+29.4%) | -$8.15 M(+7.7%) |
| Sep 2019 | - | -$2.00 M(+40.5%) | -$7.57 M(-9.4%) |
| Jun 2019 | - | -$1.42 M(-33.7%) | -$8.35 M(-5.9%) |
| Mar 2019 | - | -$2.15 M(+7.1%) | -$8.88 M(-18.1%) |
| Dec 2018 | -$10.84 M | -$2.00 M(-28.0%) | -$10.84 M(+5.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$2.78 M(+43.0%) | -$10.29 M(+2.6%) |
| Jun 2018 | - | -$1.95 M(-52.7%) | -$10.03 M(-5.1%) |
| Mar 2018 | - | -$4.11 M(+183.1%) | -$10.56 M(+63.3%) |
| Dec 2017 | -$6.47 M(-23.1%) | -$1.45 M(-42.3%) | -$6.47 M(-8.5%) |
| Sep 2017 | - | -$2.52 M(+1.6%) | -$7.07 M(+2.7%) |
| Jun 2017 | - | -$2.48 M(>+9900.0%) | -$6.88 M(-2.8%) |
| Mar 2017 | - | -$18.60 K(-99.1%) | -$7.08 M(-15.9%) |
| Dec 2016 | -$8.41 M(+88.7%) | -$2.05 M(-12.1%) | -$8.41 M(+6.4%) |
| Sep 2016 | - | -$2.33 M(-12.8%) | -$7.91 M(+37.6%) |
| Jun 2016 | - | -$2.67 M(+97.6%) | -$5.75 M(+42.1%) |
| Mar 2016 | - | -$1.35 M(-12.6%) | -$4.04 M(-9.3%) |
| Dec 2015 | -$4.46 M(+369.1%) | -$1.55 M(+813.7%) | -$4.46 M(+33.2%) |
| Sep 2015 | - | -$169.50 K(-82.6%) | -$3.35 M(+4.3%) |
| Jun 2015 | - | -$972.10 K(-45.0%) | -$3.21 M(+40.2%) |
| Mar 2015 | - | -$1.77 M(+305.6%) | -$2.29 M(+140.7%) |
| Dec 2014 | -$950.60 K(-67.9%) | -$436.10 K(+1344.0%) | -$950.60 K(-23.1%) |
| Sep 2014 | - | -$30.20 K(-43.2%) | -$1.24 M(-31.9%) |
| Jun 2014 | - | -$53.20 K(-87.7%) | -$1.81 M(-28.2%) |
| Mar 2014 | - | -$431.10 K(-40.2%) | -$2.53 M(-14.5%) |
| Dec 2013 | -$2.96 M(-43.4%) | -$721.40 K(+18.5%) | -$2.96 M(+32.3%) |
| Sep 2013 | - | -$609.00 K(-20.6%) | -$2.24 M(+37.4%) |
| Jun 2013 | - | -$767.20 K(-10.8%) | -$1.63 M(+89.2%) |
| Mar 2013 | - | -$860.00 K | -$860.00 K |
| Dec 2012 | -$5.22 M | - | - |
FAQ
- What is Kiora Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Kiora Pharmaceuticals?
- What is Kiora Pharmaceuticals annual CFO year-on-year change?
- What is Kiora Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Kiora Pharmaceuticals?
- What is Kiora Pharmaceuticals quarterly CFO year-on-year change?
- What is Kiora Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Kiora Pharmaceuticals?
- What is Kiora Pharmaceuticals TTM CFO year-on-year change?
What is Kiora Pharmaceuticals annual cash flow from operations?
The current annual CFO of KPRX is -$9.56 M
What is the all time high annual CFO for Kiora Pharmaceuticals?
Kiora Pharmaceuticals all-time high annual cash flow from operations is -$950.60 K
What is Kiora Pharmaceuticals annual CFO year-on-year change?
Over the past year, KPRX annual cash flow from operations has changed by +$871.10 K (+8.35%)
What is Kiora Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of KPRX is $920.10 K
What is the all time high quarterly CFO for Kiora Pharmaceuticals?
Kiora Pharmaceuticals all-time high quarterly cash flow from operations is $13.62 M
What is Kiora Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, KPRX quarterly cash flow from operations has changed by +$3.44 M (+136.50%)
What is Kiora Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of KPRX is $8.23 M
What is the all time high TTM CFO for Kiora Pharmaceuticals?
Kiora Pharmaceuticals all-time high TTM cash flow from operations is $8.23 M
What is Kiora Pharmaceuticals TTM CFO year-on-year change?
Over the past year, KPRX TTM cash flow from operations has changed by +$17.33 M (+190.40%)